USTRx Act
Sponsored By: Representative Rep. Arrington, Jodey C. [R-TX-19]
Introduced
Summary
This bill would create a new federal trade role to use trade tools to press high-income countries to change drug pricing and market access. It is framed to defend U.S. pharmaceutical innovation and to push foreign reimbursement systems to be more transparent, fair, and market-based.
Show full summary
- Patients and families: The bill argues that foreign price controls shift the cost of drug innovation onto U.S. patients and taxpayers and seeks to protect access to innovative treatments by pressuring other countries to recognize drug value.
- U.S. pharmaceutical manufacturers: It would establish a Chief Pharmaceutical Trade Negotiator to negotiate and enforce trade rules, coordinate on intellectual property issues, and pursue actions when high-income countries limit U.S. market access.
- Government and trade officials: Requires an annual report naming high-income countries using World Bank classifications, assessing their pharmaceutical pricing and market rules, and a 30-day plan to respond to adverse findings that can include investigations under the Trade Act.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Yearly review of foreign drug pricing
This bill would require USTR to make a yearly list of high-income countries using World Bank data. Each year, USTR would report on each country’s drug pricing and trade rules for the prior fiscal year. The report would go to House Ways and Means and Senate Finance and be posted online. If USTR finds a problem, it would have 30 days to send Congress a response plan, which could include a Trade Act investigation.
New negotiator for U.S. drug makers
This bill would create a Chief Pharmaceutical Trade Negotiator at the U.S. Trade Representative. The Chief would negotiate and enforce trade rules for U.S. drug makers. The Chief would act against high-income countries whose policies block fair market access. The Chief would also advocate for U.S. manufacturers and consumers and coordinate with the intellectual property negotiator. The role would start upon enactment.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Rep. Arrington, Jodey C. [R-TX-19]
TX • R
Cosponsors
Buchanan
FL • R
Sponsored 7/29/2025
Rep. Fleischmann, Charles J. "Chuck" [R-TN-3]
TN • R
Sponsored 7/29/2025
Tenney
NY • R
Sponsored 7/29/2025
Rep. Murphy, Gregory F. [R-NC-3]
NC • R
Sponsored 7/29/2025
Miller (WV)
WV • R
Sponsored 8/5/2025
Rep. Baird, James R. [R-IN-4]
IN • R
Sponsored 3/27/2026
Rep. Moran, Nathaniel [R-TX-1]
TX • R
Sponsored 4/20/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in